Citius Pharmaceuticals

(NASDAQ) CTXR

Current Price$0.58

Market Cap$15.21M

Since IPO (2014)-100%

5 Year-99%

1 Year-28%

1 Month-35%

Citius Pharmaceuticals Financials at a Glance

Market Cap

$15.21M

Revenue (TTM)

$5.61M

Net Income (TTM)

$53.08M

EPS (TTM)

$-2.57

P/E Ratio

-0.22

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$0.58

Volume

900,260.68

Open

$0.55

Price

$0.58

Volume

900,260.68

Open

$0.55

Previous Close

$0.58

Daily Range

$0.51 - $0.58

52-Week Range

$0.48 - $2.48

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$0.58

Volume

900,260.68

Open

$0.55

Previous Close

$0.58

Daily Range

$0.51 - $0.58

52-Week Range

$0.48 - $2.48

CTXR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Citius Pharmaceuticals

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Leonard L. Mazur, MBA

Website

www.citiuspharma.com

Headquarters

Cranford, NJ 07016, US

CTXR Financials

Key Financial Metrics (TTM)

Gross Margin

37%

Operating Margin

-10%

Net Income Margin

-9%

Return on Equity

-76%

Return on Capital

-75%

Return on Assets

-40%

Earnings Yield

-4.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.21M

Shares Outstanding

27.45M

Volume

900.26K

Avg. Volume

783.52K

Financials (TTM)

Gross Profit

$214.25K

Operating Income

$38.53M

EBITDA

$38.20M

Operating Cash Flow

$26.55M

Capital Expenditure

$0.00

Free Cash Flow

$26.55M

Cash & ST Invst.

$4.25M

Total Debt

$1.81M

Citius Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$1.67M

N/A

Gross Profit

$381.89K

N/A

Gross Margin

-22.90%

N/A

Market Cap

$15.21M

N/A

Market Cap/Employee

$661.49K

N/A

Employees

N/A

Net Income

$28.11M

-157.5%

EBITDA

$30.43M

-171.6%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Net Cash

$3.78M

+517.7%

Accounts Receivable

$1.08M

N/A

Inventory

$22.66M

+47.7%

Long Term Debt

$636.67K

-19.1%

Short Term Debt

$171.50K

+18.2%

Return on Assets

-40.05%

N/A

Return on Invested Capital

-75.38%

N/A

Free Cash Flow

$1.30M

+71.4%

Operating Cash Flow

$1.30M

+71.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

APLMApollomics, Inc.

APLMApollomics, Inc.$13.53-4.75%

ICUSeaStar Medical Holding Corporation

ICUSeaStar Medical Holding Corporation$3.97+2.06%

DAREDaré Bioscience, Inc.

DAREDaré Bioscience, Inc.$2.33+3.56%

CRISCuris, Inc.

CRISCuris, Inc.$0.50+4.08%

LNAILunai Bioworks Inc.

LNAILunai Bioworks Inc.$0.22-10.19%

ATHAAthira Pharma, Inc.

ATHAAthira Pharma, Inc.$6.75-6.12%

MBRXMoleculin Biotech, Inc.

MBRXMoleculin Biotech, Inc.$2.34-0.43%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$12.95+0.07%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.67+0.06%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.51+0.05%

NUNu Holdings

NUNu Holdings$12.79+0.04%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.19-0.05%

MARAMara Holdings

MARAMara Holdings$13.15+0.06%

BACBank of America

BACBank of America$51.23+0.01%

Questions About CTXR

What is the current price of Citius Pharmaceuticals?

Citius Pharmaceuticals is trading at $0.58 per share.

What is the 52-week range for Citius Pharmaceuticals?

Over the past 52 weeks, Citius Pharmaceuticals has traded between $0.48 and $2.48.

How much debt does Citius Pharmaceuticals have?

As of the most recent reporting period, Citius Pharmaceuticals reported total debt of $808,162.

How much cash does Citius Pharmaceuticals have on hand?

Citius Pharmaceuticals reported $4.59M in cash and cash equivalents in its most recent financial results.

What is Citius Pharmaceuticals’s dividend yield?

Citius Pharmaceuticals does not currently have a dividend yield.

Citius Pharmaceuticals

Citius Pharmaceuticals Financials at a Glance

CTXR News

Citius Posts Wider Loss in Fiscal Q3

Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?

Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today

Is It Too Late to Buy Citius Pharmaceuticals Stock?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Citius Pharmaceuticals

CTXR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Citius Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CTXR

What is the current price of Citius Pharmaceuticals?

What is the 52-week range for Citius Pharmaceuticals?

How much debt does Citius Pharmaceuticals have?

How much cash does Citius Pharmaceuticals have on hand?

What is Citius Pharmaceuticals’s dividend yield?

Premium Investing Services